RARE logo

Ultragenyx Pharmaceutical (RARE) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

31 January 2014

Indexes:

Not included

Description:

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company headquartered in Novato, California, specializing in the development and implementation of new drugs for the treatment of severe rare genetic diseases. It was founded in 2010. The company focuses its efforts on developing drugs for patients with diseases that have no treatment options. Today, there are many rare genetic diseases that do not have approved therapies. The company's product portfolio includes two commercially approved products, as well as several candidates at various stages of clinical trials, which can be divided into three categories: biologics, gene therapy products, and small molecules.

Events Calendar

Earnings

Next earnings date:

Feb 14, 2025

Recent quarterly earnings:

Nov 05, 2024

Recent annual earnings:

Feb 15, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

22 Oct '24 Cantor Fitzgerald
Overweight
21 Oct '24 TD Cowen
Buy
01 Oct '24 Cantor Fitzgerald
Overweight
26 Sept '24 RBC Capital
Outperform
20 Sept '24 Cantor Fitzgerald
Overweight
16 Sept '24 Cantor Fitzgerald
Overweight
05 Aug '24 Barclays
Overweight
02 Aug '24 Wells Fargo
Overweight
02 Aug '24 Wedbush
Neutral
02 Aug '24 Goldman Sachs
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

RARE Submits BLA to the FDA for Sanfilippo Syndrome Gene Therapy
RARE Submits BLA to the FDA for Sanfilippo Syndrome Gene Therapy
RARE Submits BLA to the FDA for Sanfilippo Syndrome Gene Therapy
RARE
zacks.com20 December 2024

Ultragenyx submits a BLA to the FDA seeking the accelerated approval of UX111 for patients with Sanfilippo syndrome type A in the United States.

HARMONY BIOSCIENCES TO PARTICIPATE IN OPPENHEIMER MOVERS IN RARE DISEASE SUMMIT
HARMONY BIOSCIENCES TO PARTICIPATE IN OPPENHEIMER MOVERS IN RARE DISEASE SUMMIT
HARMONY BIOSCIENCES TO PARTICIPATE IN OPPENHEIMER MOVERS IN RARE DISEASE SUMMIT
RARE
prnewswire.com03 December 2024

PLYMOUTH MEETING, Pa. , Dec. 3, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the upcoming Oppenheimer Movers in Rare Disease Summit in New York, NY on Thursday, December 12, 2024, at 9:00 a.m.

Ultragenyx to Participate in Investor Conferences in December
Ultragenyx to Participate in Investor Conferences in December
Ultragenyx to Participate in Investor Conferences in December
RARE
globenewswire.com26 November 2024

NOVATO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced participation in three upcoming investor conferences.

Ultragenyx: Ready For More Growth After Q3 Earnings Beat
Ultragenyx: Ready For More Growth After Q3 Earnings Beat
Ultragenyx: Ready For More Growth After Q3 Earnings Beat
RARE
seekingalpha.com12 November 2024

Ultragenyx's strong Q3 earnings report, with a 42% YoY revenue increase, has reignited my interest in initiating a starter position in RARE. The company's promising pipeline, including late-stage programs like Setrusumab and DTX401, presents multiple catalysts for future growth and higher valuation. Ultragenyx's $825M cash position and path to profitability by 2026 suggest financial stability, potentially avoiding the need for extensive dilutive financing.

Ultragenyx Pharmaceutical Inc. (RARE) Q3 2024 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2024 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2024 Earnings Call Transcript
RARE
seekingalpha.com05 November 2024

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Q3 2024 Earnings Conference Call November 5, 2024 5:00 PM ET Company Participants Joshua Higa - VP, IR Emil Kakkis - CEO and President Erik Harris - CCO Howard Horn - CFO Eric Crombez - CMO Conference Call Participants Chris Raymond - Piper Sandler Tazeen Ahmad - Bank of America Malcolm Kuno - JPMorgan Gena Wang - Barclays Lydia Erdman - Goldman Sachs Maury Raycroft - Jefferies Mehdi Goudarzi - Truist Securities Yaron Werber - TD Cowen Yigal Nochomovitz - Citi Thomas Yip - H.C. Wainwright Jack Allen - Baird Joe Schwartz - Leerink Partners Michael Riad - Morgan Stanley Kristen Kluska - Cantor Fitzgerald Dae Gon Ha - Stifel Operator Good afternoon and welcome to the Ultragenyx Third Quarter 2024 Financial Results Conference Call.

Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key Metrics
Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key Metrics
Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key Metrics
RARE
zacks.com05 November 2024

While the top- and bottom-line numbers for Ultragenyx (RARE) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates
Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates
Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates
RARE
zacks.com05 November 2024

Ultragenyx (RARE) came out with a quarterly loss of $1.40 per share versus the Zacks Consensus Estimate of a loss of $1.45. This compares to loss of $2.23 per share a year ago.

RARE's Wilson Disease Candidate Betters Standard Therapy in Study
RARE's Wilson Disease Candidate Betters Standard Therapy in Study
RARE's Wilson Disease Candidate Betters Standard Therapy in Study
RARE
zacks.com04 October 2024

Ultragenyx reports superior efficacy of UX701 for Wilson disease compared with standard therapy from the Stage 1 cohorts of its pivotal phase I/II/III study.

Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
RARE
globenewswire.com03 October 2024

NOVATO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today reported that the Phase 1/2/3 Cyprus 2+ study of its UX701 gene therapy has demonstrated meaningful clinical activity as well as improvements in copper metabolism in Stage 1. Multiple responders have completely tapered off of standard-of-care treatment with responses seen in all three dose cohorts. The company plans to enroll an additional cohort in Stage 1 at a moderately increased dose and with an optimized immunomodulation regimen to enhance the efficiency and efficacy of the gene therapy, with the objective of having the majority of patients come off of standard-of-care treatment before selecting a dose for the randomized placebo-controlled stage of the study.

Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting
Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting
Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting
RARE
globenewswire.com26 September 2024

NOVATO, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it will present seven abstracts related to its ongoing late-stage program evaluating setrusumab (UX143) and osteogenesis imperfecta (OI), including a late-breaker oral presentation of the 14-month data from the Phase 2/3 Orbit study, at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting. The meeting is being held September 27-30, 2024, in Toronto, Canada.

FAQ

  • What is the primary business of Ultragenyx Pharmaceutical?
  • What is the ticker symbol for Ultragenyx Pharmaceutical?
  • Does Ultragenyx Pharmaceutical pay dividends?
  • What sector is Ultragenyx Pharmaceutical in?
  • What industry is Ultragenyx Pharmaceutical in?
  • What country is Ultragenyx Pharmaceutical based in?
  • When did Ultragenyx Pharmaceutical go public?
  • Is Ultragenyx Pharmaceutical in the S&P 500?
  • Is Ultragenyx Pharmaceutical in the NASDAQ 100?
  • Is Ultragenyx Pharmaceutical in the Dow Jones?
  • When was Ultragenyx Pharmaceutical's last earnings report?
  • When does Ultragenyx Pharmaceutical report earnings?
  • Should I buy Ultragenyx Pharmaceutical stock now?

What is the primary business of Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company headquartered in Novato, California, specializing in the development and implementation of new drugs for the treatment of severe rare genetic diseases. It was founded in 2010. The company focuses its efforts on developing drugs for patients with diseases that have no treatment options. Today, there are many rare genetic diseases that do not have approved therapies. The company's product portfolio includes two commercially approved products, as well as several candidates at various stages of clinical trials, which can be divided into three categories: biologics, gene therapy products, and small molecules.

What is the ticker symbol for Ultragenyx Pharmaceutical?

The ticker symbol for Ultragenyx Pharmaceutical is NASDAQ:RARE

Does Ultragenyx Pharmaceutical pay dividends?

No, Ultragenyx Pharmaceutical does not pay dividends

What sector is Ultragenyx Pharmaceutical in?

Ultragenyx Pharmaceutical is in the Healthcare sector

What industry is Ultragenyx Pharmaceutical in?

Ultragenyx Pharmaceutical is in the Biotechnology industry

What country is Ultragenyx Pharmaceutical based in?

Ultragenyx Pharmaceutical is headquartered in United States

When did Ultragenyx Pharmaceutical go public?

Ultragenyx Pharmaceutical's initial public offering (IPO) was on 31 January 2014

Is Ultragenyx Pharmaceutical in the S&P 500?

No, Ultragenyx Pharmaceutical is not included in the S&P 500 index

Is Ultragenyx Pharmaceutical in the NASDAQ 100?

No, Ultragenyx Pharmaceutical is not included in the NASDAQ 100 index

Is Ultragenyx Pharmaceutical in the Dow Jones?

No, Ultragenyx Pharmaceutical is not included in the Dow Jones index

When was Ultragenyx Pharmaceutical's last earnings report?

Ultragenyx Pharmaceutical's most recent earnings report was on 5 November 2024

When does Ultragenyx Pharmaceutical report earnings?

The next expected earnings date for Ultragenyx Pharmaceutical is 14 February 2025

Should I buy Ultragenyx Pharmaceutical stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions